Topic:	Diabetes (DM)
Title:	Insulin Glulisine Provides Improved Glycemic Control in Patients With Type 2 Diabetes.
Author:	Dailey, G., et al.
Source:	Diabetes Care. 27(10): 2363-2368. October 2004.
Abstract:	Insulin glulisine is a new analog of human insulin designed for use as a rapid-acting insulin. This article reports on a study that compared the safety and effectiveness of glulisine with regular human insulin (RHI) in combination with NPH insulin. The authors studied 876 relatively well-controlled patients with type 2 diabetes (mean HbA1c levels 7.55 percent). Patients were treated with glulisine and NPH (n = 435) or RHI and NPH (n = 441) for up to 26 weeks in this randomized, multicenter, open label, parallel group study. Subjects continued to use the same dose of prestudy regimens of oral antidiabetes agents, unless hypoglycemia necessitated a dose change. Results showed a slightly greater reduction from baseline to end point HbA1c in the glulisine group versus RHI. Also at end point, lower postbreakfast and postdinner blood glucose levels were noted. Symptomatic hypoglycemia and weight gain were comparable between the two treatment groups. The authors conclude that twice-daily glulisine associated with NPH can provide small improvements in glycemic control compared with RHI in patients with type 2 diabetes who are already relatively well controlled on insulin alone or insulin plus oral antidiabetes drugs. 2 figures. 1 table. 14 references.
Format:	Journal Article
Language:	English.
Major Keywords:	Diabetes Mellitus. Blood Glucose. Drug Therapy. Insulin. Administration and Dosage. Insulin Glulisine.
Minor Keywords:	Hypoglycemia. Oral Hypoglycemia Agents. Glycosylated Hemoglobin. Body Weight. Patient Care Management. Drug Effects.
Publication Number:	DMJA12051
Return to Search Results